The experimental results of Benzyl Ntertbutyloxycarbonylβcyclohexylaspartate(Ⅰ)were reported in this paper.Starting from cheap and accessible Laspartic acid,the key intermediate of βcyclohexyl Ntertbutyloxycarbonyl...The experimental results of Benzyl Ntertbutyloxycarbonylβcyclohexylaspartate(Ⅰ)were reported in this paper.Starting from cheap and accessible Laspartic acid,the key intermediate of βcyclohexyl Ntertbutyloxycarbonylaspartate(Ⅱ)was prepared by esterification of aspartic acid via cyclohexanol catalyzed by sulfuric acid and further acylation via Boc2O.The synthesis of the title compound of(Ⅰ)was performed by benzylization of(Ⅱ)through benzyl bromide.The method is facile and the yield is higher than that in literatures.The structures of these compounds were verified by1H NMR and mp.,or by the corresponding authentic compounds.The discussion of the preparative conditions of Ⅰ and Ⅱ was also given.展开更多
Momordica antiviral protein 30 kD(MAP30)is a type I ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To increase its tumor-targeting ab...Momordica antiviral protein 30 kD(MAP30)is a type I ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To increase its tumor-targeting ability,the arginine-glycine-aspartic(RGD)peptide and the epidermal growth factor receptor interference(EGFRi)peptide were fused with MAP30,which was named ELRL-MAP30.The efficiency of targeted therapy for triple-negative breast cancer(TNBC)MDA-MB-231 cells,which lack the expression of estrogen receptor(ER),Progesterone receptor(PgR)and human epidermal growth factor receptor-2(HER2),is limited.In this study,we focus on exploring the effect and mechanism of ELRL-MAP30 on TNBC MDA-MB-231 cells.First,we discovered that ELRL-MAP30 significantly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis.Moreover,ELRL-MAP30 treatment resulted in a significant increase in Bax expression and a decrease in Bcl-2 expression.Furthermore,ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways.In addition,recombinant ELRL-MAP30 can inhibit chicken embryonic angiogenesis,and also inhibit the tube formation ability of human umbilical vein endothelial cells(HUVECs),indicating its potential therapeutic effects on tumor angiogenesis.Collectively,these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential therapeutic effects on angiogenesis.These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.展开更多
文摘The experimental results of Benzyl Ntertbutyloxycarbonylβcyclohexylaspartate(Ⅰ)were reported in this paper.Starting from cheap and accessible Laspartic acid,the key intermediate of βcyclohexyl Ntertbutyloxycarbonylaspartate(Ⅱ)was prepared by esterification of aspartic acid via cyclohexanol catalyzed by sulfuric acid and further acylation via Boc2O.The synthesis of the title compound of(Ⅰ)was performed by benzylization of(Ⅱ)through benzyl bromide.The method is facile and the yield is higher than that in literatures.The structures of these compounds were verified by1H NMR and mp.,or by the corresponding authentic compounds.The discussion of the preparative conditions of Ⅰ and Ⅱ was also given.
文摘Momordica antiviral protein 30 kD(MAP30)is a type I ribosome-inactivating protein(RIP)with antibacterial,anti-HIV and antitumor activities but lacks the ability to target tumor cells.To increase its tumor-targeting ability,the arginine-glycine-aspartic(RGD)peptide and the epidermal growth factor receptor interference(EGFRi)peptide were fused with MAP30,which was named ELRL-MAP30.The efficiency of targeted therapy for triple-negative breast cancer(TNBC)MDA-MB-231 cells,which lack the expression of estrogen receptor(ER),Progesterone receptor(PgR)and human epidermal growth factor receptor-2(HER2),is limited.In this study,we focus on exploring the effect and mechanism of ELRL-MAP30 on TNBC MDA-MB-231 cells.First,we discovered that ELRL-MAP30 significantly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis.Moreover,ELRL-MAP30 treatment resulted in a significant increase in Bax expression and a decrease in Bcl-2 expression.Furthermore,ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways.In addition,recombinant ELRL-MAP30 can inhibit chicken embryonic angiogenesis,and also inhibit the tube formation ability of human umbilical vein endothelial cells(HUVECs),indicating its potential therapeutic effects on tumor angiogenesis.Collectively,these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential therapeutic effects on angiogenesis.These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.
